S. Tjulandin

3.5k total citations · 1 hit paper
75 papers, 2.1k citations indexed

About

S. Tjulandin is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, S. Tjulandin has authored 75 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 51 papers in Oncology, 23 papers in Pulmonary and Respiratory Medicine and 17 papers in Surgery. Recurrent topics in S. Tjulandin's work include Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and HER2/EGFR in Cancer Research (16 papers). S. Tjulandin is often cited by papers focused on Cancer Treatment and Pharmacology (18 papers), Colorectal Cancer Treatments and Studies (17 papers) and HER2/EGFR in Cancer Research (16 papers). S. Tjulandin collaborates with scholars based in Russia, United States and United Kingdom. S. Tjulandin's co-authors include Semiglazov Vf, Aňa Lluch, W. Eiermann, Alexey Manikhas, Mikhail Lichinitser, Pinuccia Valagussa, Luca Gianni, José Baselga, A. Feyereislova and Milvia Zambetti and has published in prestigious journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

S. Tjulandin

67 papers receiving 2.0k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort

2010 891 citations Alexey Manikhas, Aňa Lluch et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
S. Tjulandin Russia	20	1.4k	724	596	520	357	75	2.1k
D. Fennelly Ireland	25	1.8k 1.3×	377 0.5×	564 0.9×	878 1.7×	157 0.4×	85	2.6k
Megumi Ishiguro Japan	27	1.4k 1.0×	301 0.4×	555 0.9×	608 1.2×	105 0.3×	103	2.1k
H. Curé France	22	1.2k 0.9×	742 1.0×	327 0.5×	367 0.7×	118 0.3×	82	2.0k
Eiji Shinto Japan	27	1.9k 1.4×	254 0.4×	629 1.1×	863 1.7×	164 0.5×	116	2.4k
Cristina Grávalos Spain	23	1.7k 1.2×	319 0.4×	960 1.6×	426 0.8×	314 0.9×	81	2.3k
A. Hennipman Netherlands	21	1.6k 1.2×	500 0.7×	884 1.5×	754 1.4×	166 0.5×	39	2.6k
Olivier Dubreuil France	15	932 0.7×	382 0.5×	498 0.8×	378 0.7×	166 0.5×	56	1.6k
Francesco Sclafani United Kingdom	24	1.2k 0.9×	323 0.4×	440 0.7×	593 1.1×	195 0.5×	121	1.9k
Vicente Morales‐Oyarvide United States	30	2.2k 1.6×	520 0.7×	1.1k 1.8×	1.3k 2.5×	141 0.4×	54	3.0k
Sami Diab United States	27	1.8k 1.3×	1.0k 1.4×	805 1.4×	224 0.4×	152 0.4×	74	2.8k

Countries citing papers authored by S. Tjulandin

Since Specialization

Citations

This map shows the geographic impact of S. Tjulandin's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Tjulandin with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Tjulandin more than expected).

Fields of papers citing papers by S. Tjulandin

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Tjulandin. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Tjulandin. The network helps show where S. Tjulandin may publish in the future.

Co-authorship network of co-authors of S. Tjulandin

This figure shows the co-authorship network connecting the top 25 collaborators of S. Tjulandin. A scholar is included among the top collaborators of S. Tjulandin based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Tjulandin. S. Tjulandin is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fadeeva, Natalia, Rajnish Nagarkar, Hryhoriy Adamchuk, et al.. (2021). 1338P A phase III study comparing BCD-021, a bevacizumab biosimilar, and reference bevacizumab in patients with stage IIIB or IV non-squamous NSCLC. Annals of Oncology. 32. S1022–S1022. 1 indexed citations

Завалишина, Л Э, et al.. (2019). Assessment of PD-L1 expression in patients with urothelial cancer with contraindications to platinum based therapy. Malignant tumours. 9(1). 10–15. 1 indexed citations

Fedyanin, М. Yu., И. А. Покатаев, A. Tryakin, et al.. (2018). Role of adjuvant chemotherapy in patients with rectal cancer after preoperative chemoradiotherapy: results of a retrospective study. SHILAP Revista de lepidopterología. 8(2). 24–37. 1 indexed citations

Покатаев, И. А., et al.. (2018). Efficacy and safety of FOLFIRINOX induction chemotherapy in borderline resectable and unresectable pancreatic cancer. Malignant tumours. 8(1). 38–47. 1 indexed citations

Богуш, Т. А., et al.. (2017). Flow cytometric analysis of the ERCC1, marker of DNA damage repair, in the tumor specimens embedded into paraffin blocks. Doklady Biochemistry and Biophysics. 472(1). 9–11. 2 indexed citations

Tryakin, A., et al.. (2017). Reproductive function in patients with malignant ovarian germ cell tumours. Malignant tumours. 47–53. 1 indexed citations

Tryakin, A., et al.. (2017). Treatment of patients with poor risk nonseminomatous germ cell tumors at advanced stages. Malignant tumours. 23–29.

Han, Baohui, M. Ratcliffe, Vincent Haddad, et al.. (2016). 59PD Association of EGFR mutation subtypes with clinical and demographic characteristics of patients (pts) with aNSCLC: IGNITE and ASSESS pooled analysis. Journal of Thoracic Oncology. 11(4). S79–S80. 1 indexed citations

Савелов, Н. А., А. И. Карселадзе, A. Tryakin, et al.. (2016). Nuclear Protein of the Testis Midline Carcinoma Masquerading as a Primary Mediastinal Seminoma. Rare Tumors. 8(2). 85–87. 3 indexed citations

10.

Fedyanin, М. Yu., A. Tryakin, & S. Tjulandin. (2015). Role of microsatellite instability in colon cancer. SHILAP Revista de lepidopterología. 2 indexed citations

11.

Fedyanin, М. Yu., A. Tryakin, & S. Tjulandin. (2015). Chemotherapy of metastatic colon cancer. SHILAP Revista de lepidopterología. 1 indexed citations

12.

Богуш, Т. А., et al.. (2015). The Comparative Estimation of TUBB3 Expression in Non-Small-Cell Lung Carcinoma and Adjacent Lung Tissue. Annals of Oncology. 26. i10–i10. 1 indexed citations

13.

Iveson, Timothy, Ross C. Donehower, Ірина Давиденко, et al.. (2014). Rilotumumab in combination with epirubicin, cisplatin, and capecitabine as first-line treatment for gastric or oesophagogastric junction adenocarcinoma: an open-label, dose de-escalation phase 1b study and a double-blind, randomised phase 2 study. The Lancet Oncology. 15(9). 1007–1018. 216 indexed citations

14.

Tjulandin, S., Vladimir Moiseyenko, В. В. Семиглазов, et al.. (2013). Phase I, dose-finding study of AZD8931, an inhibitor of EGFR (erbB1), HER2 (erbB2) and HER3 (erbB3) signaling, in patients with advanced solid tumors. Investigational New Drugs. 32(1). 145–153. 21 indexed citations

15.

Fedyanin, М. Yu., et al.. (2013). Prognostic factors and efficacy of different chemotherapeutic regimens in patients with mediastinal nonseminomatous germ cell tumors. Journal of Cancer Research and Clinical Oncology. 140(2). 311–318. 10 indexed citations

16.

Tjulandin, S., Anatoly Makhson, Joseph Gligorov, et al.. (2011). First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC.. Journal of Clinical Oncology. 29(15_suppl). 571–571. 2 indexed citations

17.

Tjulandin, S., et al.. (2008). Targeted therapy in the treatment of solid tumors: Practice contradicts theory. Biochemistry (Moscow). 73(5). 605–618. 37 indexed citations

18.

Capizzi, Robert L., L Roman, S. Tjulandin, et al.. (2008). Phase II trial of C1311, a novel inhibitor of topoisomerase II in advanced breast cancer. Journal of Clinical Oncology. 26(15_suppl). 1055–1055. 25 indexed citations

19.

Gurtler, Jayne, Laura H. Goldstein, S. Tjulandin, et al.. (2005). Trabectedin in third line breast cancer: A multicenter, randomized, phase II study comparing two administration regimens. Journal of Clinical Oncology. 23(16_suppl). 625–625. 22 indexed citations

20.

Tjulandin, S., A. Garin, Н И Переводчикова, et al.. (1993). Cisplatin-etoposide and carboplatin-etoposide induction chemotherapy for good-risk patients with germ cell tumor. Annals of Oncology. 4(8). 663–667. 16 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact